

Epidemiology of Bloodstream Infections in Solid Organ Transplant Recipients UTSouthwestern

Terrence Liu, MS2; Ricardo La Hoz, MD¹; David Greenberg, MD^{1,2}

¹Department of Internal Medicine, ²Department of Microbiology, University of Texas Southwestern Medical Center

Medical Center

Introduction

Infection represents one of the most common and serious complications following solid organ transplantation (SOT). In particular, bloodstream infections (BSIs) are associated with considerable morbidity and mortality in transplant patients. Creating a transplant database that characterizes key infectious disease parameters such as risk factors, bacterial etiology, and antibiotic susceptibility could have tremendous implications for reducing the burden of infectious complications in transplant recipients. Our aim in this study is to describe the epidemiology of BSI in SOT recipients at UTSW.

Methods

The design of the study was a retrospective single center cohort study. A total of 837 solid organ transplantations performed at UTSW between 1/1/2010 and 6/30/2015 were included in the study. The duration of follow-up was 1 year. BSI episodes were defined as positive cultures separated by ≥7 days. Positive cultures of the same organism in a patient <7 days apart counted as a single BSI episode. Positive cultures of different organisms in a patient <7 days apart counted as discrete BSI episodes for that particular organism. Innovative data mining tools were utilized to extract demographic, clinical and laboratory information from the electronic medical record. Through the UTSW Clinical Research Data Warehouse, we were able to extract over 600 discreet variables from a database server (Clarity) through an automated process with high precision. We connected this database with additional databases such as the Social Security Death Index (SSDI) and Scientific Registry of Transplant Recipients database (SRTR) to obtain data necessary for construction of Kaplan-Meier survival curves with censorship. Based on our inclusion criteria, we identified study subjects and extracted the following variables: patient demographics, positive blood cultures, date of surgery, transplanted organ and date of death.

Results

Table 1. Demographics			
Characteristic	All transplant patients (n=837)	Patients with negative cultures (n=777)	Patients with ≥1 positive culture (n=60)
Sex			
Male	541 (65%)	502 (65%)	39 (65%)
Female	296 (35%)	275 (35%)	21 (35%)
Age			
Mean ± SD	53.8 ± 13.2	53.8 ± 13	53.6 ± 15
Median (Range)	57 (14-83)	57 (14-80)	57 (16-83)
Race			
White	560 (67%)	522 (67%)	38 (63%)
African American	128 (15%)	119 (15%)	9 (15%)
Asian	27 (3%)	25 (3%)	2 (3%)
Other	76 (9%)	68 (9%)	8 (14%)
Unknown	46 (6%)	43 (6%)	3 (5%)
Organ			
Heart	152 (18%)	140 (18%)	12 (20%)
Kidney	217 (26%)	206 (26%)	11 (18%)
Liver	147 (18%)	133 (17%)	14 (23%)
Lung	296 (35%)	277 (36%)	19 (32%)
Simultaneous	25 (3%)	21 (3%)	4 (7%)





Figure 1. Distribution of BSI episodes by Gram staining of causative organism








Figure 5. Onset of first BSI episode post transplantation

Table 2. Cumulative incidence and incidence rate of first positive blood culture over one year of follow-upOverallHeartKidneyLiverLungSimultaneousCumulative Incidence (%)11.815.17.414.311.816




Figure 3. Cumulative Incidence of first positive blood culture by day post-transplant




Figure 4. Kaplan Meier survival curve of all-cause mortality among solid organ transplant recipients (SOT) with negative cultures versus SOT recipients with at least one positive culture (P < 0.0001 by log-rank)

Conclusion

- The cumulative incidence of BSI at 1-year post-transplantation for all organs was 11.8%. The highest BSI cumulative incidence occurred in simultaneous SOT recipients (16.0%), suggesting that patients undergoing simultaneous organ transplantation may be at a higher risk of acquiring a BSI compared to other types of transplantations. The organ group with the next highest BSI cumulative incidence were heart transplants (15.1%)
- The most common microorganisms identified were *S. epidermidis* (15.38%), *E. Coli* (15.38%), *Klebsiella sp.* (12.82%), *P. aeruginosa* (12.82%), and Vancomycin-resistant *E. faecium* (11.54%). Further analysis is necessary to determine source of infection and whether they constitute true BSIs or contaminants under CDC/NHSN guidelines
- The timing of the first episode of BSI was as follows: twenty-one episodes (35%) occurred during the first month, 27 (45%) between 1 and 6 months and 12 (20%) after 6 months post-transplantation. Most of the first BSI episodes occurred > 1 month post-transplantation (39, 65%), potentially highlighting a particularly vulnerable period for SOT recipients
- The median time to onset of first BSI episode after transplantation was 67 days (range: 0-354 days)
- The all-cause mortality in SOT recipients with at least one positive culture was greater than the SOT recipients with negative cultures
- Further studies and multivariate analysis are underway to identify independent risk factors for BSI acquisition and patient outcomes

References

Berenger, B. M., et al. (2016). "Epidemiology and risk factors for nosocomial bloodstream infections in solid organ transplants over a 10-year period." <u>Transpl Infect Dis</u> **18**(2): 183-190.

Malinis, M. F., et al. (2012). "Staphylococcus aureus bacteremia in solid organ transplant recipients: evidence for improved survival when compared with nontransplant patients." <u>Transplantation</u> **93**(10): 1045-1050.

Moreno, A., et al. (2007). "Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain." Am J Transplant 7(11): 2579-2586.

Wagener, M. M. and V. L. Yu (1992). "Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes." <u>Am J Infect Control</u> **20**(5): 239-247.

Acknowledgements

UT Southwestern Medical Student Research Program
Department of Internal Medicine, UTSW

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health" under award Number UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH